Literature DB >> 24280882

Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Millie D Long1, Susan Hutfless, Michael D Kappelman, Hamed Khalili, Gilaad G Kaplan, Charles N Bernstein, Jean Frederic Colombel, Corinne Gower-Rousseau, Lisa Herrinton, Fernando Velayos, Edward V Loftus, Geoffrey C Nguyen, Ashwin N Ananthakrishnan, Amnon Sonnenberg, Andrew Chan, Robert S Sandler, Ashish Atreja, Samir A Shah, Kenneth J Rothman, Neal S Leleiko, Renee Bright, Paolo Boffetta, Kelly D Myers, Bruce E Sands.   

Abstract

This review describes the history of U.S. government funding for surveillance programs in inflammatory bowel diseases (IBD), provides current estimates of the incidence and prevalence of IBD in the United States, and enumerates a number of challenges faced by current and future IBD surveillance programs. A rationale for expanding the focus of IBD surveillance beyond counts of incidence and prevalence, to provide a greater understanding of the burden of IBD, disease etiology, and pathogenesis, is provided. Lessons learned from other countries are summarized, in addition to potential resources that may be used to optimize a new form of IBD surveillance in the United States. A consensus recommendation on the goals and available resources for a new model for disease surveillance are provided. This new model should focus on "surveillance of the burden of disease," including (1) natural history of disease and (2) outcomes and complications of the disease and/or treatments.

Entities:  

Mesh:

Year:  2014        PMID: 24280882      PMCID: PMC4610029          DOI: 10.1097/01.MIB.0000435441.30107.8b

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  108 in total

1.  OSCCAR: Ocean State Crohn's and Colitis Area Registry.

Authors:  Bruce E Sands; Neal LeLeiko; Samir A Shah; Renee Bright; Stacey Grabert
Journal:  Med Health R I       Date:  2009-03

2.  Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002.

Authors:  Lisa J Herrinton; Liyan Liu; James D Lewis; Patricia M Griffin; James Allison
Journal:  Am J Gastroenterol       Date:  2008-08       Impact factor: 10.864

Review 3.  Using technology to promote gastrointestinal outcomes research: a case for electronic health records.

Authors:  Ashish Atreja; Jean-Paul Achkar; Anil K Jain; C Martin Harris; Bret A Lashner
Journal:  Am J Gastroenterol       Date:  2008-09       Impact factor: 10.864

Review 4.  Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases.

Authors:  Charles N Bernstein; Fergus Shanahan
Journal:  Gut       Date:  2008-05-30       Impact factor: 23.059

5.  Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization.

Authors:  Xiaoping Weng; Liyan Liu; Lisa F Barcellos; James E Allison; Lisa J Herrinton
Journal:  Am J Gastroenterol       Date:  2007-04-16       Impact factor: 10.864

6.  Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Carol Q Porter; Daniel A Ollendorf; Robert S Sandler; Joseph A Galanko; Jonathan A Finkelstein
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

7.  Natural history of pediatric Crohn's disease: a population-based cohort study.

Authors:  Gwenola Vernier-Massouille; Mamadou Balde; Julia Salleron; Dominique Turck; Jean Louis Dupas; Olivier Mouterde; Véronique Merle; Jean Louis Salomez; Julien Branche; Raymond Marti; Eric Lerebours; Antoine Cortot; Corinne Gower-Rousseau; Jean Frédéric Colombel
Journal:  Gastroenterology       Date:  2008-07-03       Impact factor: 22.682

8.  The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States.

Authors:  Michael D Kappelman; Sheryl L Rifas-Shiman; Ken Kleinman; Dan Ollendorf; Athos Bousvaros; Richard J Grand; Jonathan A Finkelstein
Journal:  Clin Gastroenterol Hepatol       Date:  2007-09-29       Impact factor: 11.382

9.  Hospitalizations for inflammatory bowel disease among US military veterans 1975-2006.

Authors:  Amnon Sonnenberg; Peter A Richardson; Neena S Abraham
Journal:  Dig Dis Sci       Date:  2009-03-04       Impact factor: 3.199

10.  Mortality by medication use among patients with inflammatory bowel disease, 1996-2003.

Authors:  Susan M Hutfless; Xiaoping Weng; Liyan Liu; James Allison; Lisa J Herrinton
Journal:  Gastroenterology       Date:  2007-09-26       Impact factor: 22.682

View more
  12 in total

1.  Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database.

Authors:  Edward L Barnes; Bharati Kochar; Millie D Long; Michael D Kappelman; Christopher F Martin; Joshua R Korzenik; Seth D Crockett
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

2.  Peroxisome Proliferator-activated Receptor-γ Coactivator 1-α (PGC1α) Protects against Experimental Murine Colitis.

Authors:  Kellie E Cunningham; Garret Vincent; Chhinder P Sodhi; Elizabeth A Novak; Sarangarajan Ranganathan; Charlotte E Egan; Donna Beer Stolz; Matthew B Rogers; Brian Firek; Michael J Morowitz; George K Gittes; Brian S Zuckerbraun; David J Hackam; Kevin P Mollen
Journal:  J Biol Chem       Date:  2016-03-11       Impact factor: 5.157

3.  Patients With Pouchitis Demonstrate a Significant Cost Burden in the First Two Years After Ileal Pouch-Anal Anastomosis.

Authors:  Edward L Barnes; Michael D Kappelman; Xian Zhang; Millie D Long; Robert S Sandler; Hans H Herfarth
Journal:  Clin Gastroenterol Hepatol       Date:  2021-10-02       Impact factor: 11.382

Review 4.  Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.

Authors:  Lauren N Cherry; Nancy S Yunker; Erika R Lambert; DaleMarie Vaughan; Denise K Lowe
Journal:  Ther Adv Chronic Dis       Date:  2015-09       Impact factor: 5.091

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.

Authors:  Amy Hemperly; Niels Vande Casteele
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

6.  Transition readiness in pediatric patients with inflammatory bowel disease: patient survey of self-management skills.

Authors:  Emily P Whitfield; Emily M Fredericks; Sally J Eder; Benjamin H Shpeen; Jeremy Adler
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-01       Impact factor: 2.839

7.  The Cumulative Incidence of Pouchitis in Pediatric Patients With Ulcerative Colitis.

Authors:  Ellen Cowherd; Matthew D Egberg; Michael D Kappelman; Xian Zhang; Millie D Long; Amy L Lightner; Robert S Sandler; Hans H Herfarth; Edward L Barnes
Journal:  Inflamm Bowel Dis       Date:  2022-09-01       Impact factor: 7.290

8.  Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis.

Authors:  Edward L Barnes; Hans H Herfarth; Michael D Kappelman; Xian Zhang; Amy Lightner; Millie D Long; Robert S Sandler
Journal:  Clin Gastroenterol Hepatol       Date:  2020-06-22       Impact factor: 13.576

Review 9.  NOD-like receptors in intestinal homeostasis and epithelial tissue repair.

Authors:  Marianna Parlato; Garabet Yeretssian
Journal:  Int J Mol Sci       Date:  2014-05-30       Impact factor: 5.923

10.  Health-Risk Behaviors and Chronic Conditions Among Adults with Inflammatory Bowel Disease - United States, 2015 and 2016.

Authors:  Fang Xu; James M Dahlhamer; Emily P Zammitti; Anne G Wheaton; Janet B Croft
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-02-16       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.